Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

Involved field irradiation: Involved field irradiation; intensity-modulated radiation therapy

Elective field irradiation: Elective field irradiation; intensity-modulated radiation therapy

Paclitaxel: Paclitaxel 135-150mg/m2, d1, every 3 weeks

Platinum: for lobaplatin, 30mg/m2, d1-2, total dose should not exceed 50mg,every 3 weeks; for nedaplatin 50mg/m2, d1-2, every 3 weeks;

PEG-rhG-CSF: PEG-rhG-CSF 3-6mg, 48 hours after chemotherapy

Study summary

Currently, adjuvant therapy is not recommended for patients with esophageal squamous cell carcinoma who received radical surgery. However, the recurrence rate is as high as 23.8%-58%, and the median time-to-recurrence is about 10.5 months. In patients who had residual tumor after surgery, evidence lacks for chemoradiation. The aim of the study is to evaluate the efficacy and safety of chemoradiation therapy in patients with recurrences after radical surgery or palliative surgery.

Eligibility

Primary outcome measure(s)

• 1-, 2-, 3-year overall survival — From treatment initiation to death from any cause or censor, assessed up to 36 months
  Overall survival

Trial sites (1)

More Chinese Academy of Medical Sciences trials in China

Other trials for the same condition